HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Bafna Pharmaceuticals Ltd Stock Comparison

Alivus Life Sciences Ltd vs Bafna Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1067 as of 16 Jul 15:15.
  • The P/E Ratio of Alivus Life Sciences Ltd is 0 as of March 2020 .The P/E Ratio of Bafna Pharmaceuticals Ltd is 0 as of March 2020.
  • The Market Cap of Alivus Life Sciences Ltd is ₹ 0 crore as of March 2020 .The Market Cap of Bafna Pharmaceuticals Ltd is ₹ 2.1 crore as of March 2020.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 659.63 crore as compare to the Dec '24 revenue of ₹ 652.3 crore. This represent the growth of 1.12% The revenue of Bafna Pharmaceuticals Ltd for the Mar '25 is ₹ 40.09 crore as compare to the Dec '24 revenue of ₹ 33.38 crore. This represent the growth of 20.1%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 208.52 crore as compare to the Dec '24 ebitda of ₹ 200.76 crore. This represent the growth of 3.87% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '25 is ₹ 2.35 crore as compare to the Dec '24 ebitda of ₹ 3.24 crore. This represent the decline of -27.47%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 135.45 crore to ₹ 141.87 crore over 8 quarters. This represents a CAGR of 2.34% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 6.35 crore to ₹ 1.31 crore over 8 quarters. This represents a CAGR of -54.58% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Bafna Pharmaceuticals Ltd

  • Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products.
  • The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
  • Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
  • During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Bafna Pharmaceuticals Ltd News Hub

News

Bafna Pharmaceuticals to table results

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 M...

Read more

21 May 2025 10:24

News

Bafna Pharmaceuticals announces board meeting date

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 Fe...

Read more

28 Jan 2025 17:34

News

Bafna Pharmaceuticals to discuss results

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 N...

Read more

04 Nov 2024 18:39

News

Bafna Pharmaceuticals schedules AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will ...

Read more

05 Sep 2024 10:29

News

Bafna Pharmaceuticals to convene AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will ...

Read more

04 Sep 2024 17:49

News

Bafna Pharmaceuticals to declare Quarterly Result

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 A...

Read more

10 Aug 2024 13:56

SWOT Analysis Of Bafna Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Bafna Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Bafna Pharmaceuticals Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Bafna Pharmaceuticals Ltd?

Market cap of Alivus Life Sciences Ltd is 12,933 Cr while Market cap of Bafna Pharmaceuticals Ltd is 208 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Bafna Pharmaceuticals Ltd?

The stock performance of Alivus Life Sciences Ltd and Bafna Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Bafna Pharmaceuticals Ltd?

As of July 16, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1054.7. On the other hand, Bafna Pharmaceuticals Ltd stock price is INR ₹88.0.

How do dividend payouts of Alivus Life Sciences Ltd and Bafna Pharmaceuticals Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Bafna Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions